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h  i  g  h  l i  g  h  t  s
• Human  embryonic  stem  cell  derived  neurons  develop  NMDA  and  AMPA  receptors  in  culture.
• Enriched  HESC-derived  neurons  develop  functional  glutamate  responses  in  vitro.
• MK  801  confers  a protective  effect  on  glutamate-induced  excitotoxic  neuronal  death.
• Studies  using  human  pluripotent  stem  cells  may  aid  the discovery  of  novel  therapeutic  targets.
a  r  t  i  c  l  e  i  n  f  o
Article history:
Received 20 December 2012
Received in revised form 28 February 2013
Accepted 10 March 2013
Keywords:
Human pluripotent stem cells
MK  801
Excitotoxicity
Glutamate
Disease-modelling
a  b  s  t  r  a  c t
Thanks  to the  development  of  efﬁcient  differentiation  strategies,  human  pluripotent  stem  cells  (HPSC)
offer  the opportunity  for  modelling  neuronal  injury  and  dysfunction  in  human  neurons  in vitro.  Critically,
the effective  use  of  HPSC-derived  neural  cells  in  disease-modelling  and  potentially  cell replacement
therapies  hinges  on  an  understanding  of  the  biology  of these  cells,  speciﬁcally  their  development,  sub-
type speciﬁcation  and  responses  to  neurotoxic  signalling  mediators.  Here,  we  generated  neurons  from
human  embryonic  stem  cells  and  characterised  the  development  of  vulnerability  to  glutamate  excito-
toxicity,  a key  contributor  to neuronal  injury  in several  acute  and  chronic  neurodegenerative  disorders.
Over  two  months  of  differentiation  we  observed  a gradual  increase  in responsiveness  of neurons  to
glutamate-induced  Ca2+ inﬂux,  attributable  to  NMDA  receptor  activity.  This  increase  was  concomitant
with  an  increase  in  expression  of mRNA  encoding  NMDA  and  AMPA  receptor  subunits.  Differentiated
neurons were  vulnerable  to  glutamate  excitotoxicity  in a  dose-dependent  manner,  which  was  reduced
by NMDA  receptor  antagonists.
© 2013 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Glutamate excitotoxicity, both acute and chronic, has been
implicated widely in the pathogenesis of a range of neurologi-
cal diseases, including Alzheimer’s disease, Huntington’s disease
and traumatic brain injury [25,28]. Knowledge of the role and
mechanisms of glutamate excitotoxicity can potentially enhance
our understanding of key downstream signalling processes that
Abbreviations: aCSF, artiﬁcial cerebrospinal ﬂuid; AMPA, 2-amino-3-(5-methyl-
3-oxo-1,2-oxazol-4-yl)propanoic acid; AMPAR, 2-amino-3-(5-methyl-3-oxo-1,2-
oxazol-4-yl)propanoic acid receptor; D-APV, aminophosphonopentanoic acid;
HESC, human embryonic stem cell; HPSC, human pluripotent stem cell; iPSC,
induced pluripotent stem cell; NPC, neural precursor cell; NMDA, N-methyl-d-
aspartic acid; NMDAR, N-methyl-d-aspartic acid receptor.
∗ Corresponding author at: Department of Neurological Surgery, Oregon Health
and Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA.
E-mail address: kg244@cantab.net (K. Gupta).
mediate neuronal death and identify novel therapeutic targets. A
major cause of glutamate excitotoxicity is activation of the NMDA
subtype of glutamate receptor (NMDAR), which mediates Ca2+-
dependent cell death [26]. Most NMDARs contain two  obligate
GluN1 subunits plus two  GluN2 subunits [11], of which there
are four subtypes, GluN2A-D, with GluN2A and GluN2B predom-
inant in the forebrain [30,40]. While physiological patterns of
synaptic NMDAR activity have the potential to be neuroprotective
[15,19,39], excessive or inappropriate activity is harmful. The work
of many laboratories has advanced our understanding of how loss of
glutamate homeostasis, ionic imbalance and inappropriate NMDAR
activity can contribute to degenerative disorders [8,16,22,25,27].
Antagonism of pathological glutamate-signalling in rodent
models of neurological diseases has yielded promising results
[6,10], though unsuccessful clinical trials highlight the need for
further studies [1,31]. Currently, excitotoxic neuronal cell death
has primarily been characterised in rodent systems. Advances
in human pluripotent stem cell (HPSC) technology permit the
0304-3940/$ – see front matter ©  2013 Elsevier Ireland Ltd. All rights reserved.
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generation of enriched neurons of differing positional identities as
well as astrocytes from human embryonic stem cells (HESC) and
allow investigation of cell injury and rescue paradigms in a human
in vitro system [12,13,23,24,35,38]. In light of the inter-species dif-
ferences between rodent and human [34], studies utilising human
in vitro systems may  prove informative in interpreting the rel-
evance of ﬁndings in rodent studies to the human pathological
condition [3,13,18].
Here, we describe the functional maturation of HESC-derived
neurons and the development of glutamate-responsiveness, in
order to study neuronal responses to pathologically relevant gluta-
mate concentrations [5].
2. Materials and methods
HESC Culture and neuralisation: The human embryonic stem
cell (HESC) line H9 (Harvard University, Cambridge, MA)  was cul-
tured and passaged regularly on a feeder layer of irradiated mouse
embryonic ﬁbroblasts, and neuralised by established protocols [21].
HESC-derived neurons were generated by methodologies described
by Koch et al. [23]. Enriched HESC-derived neural precursor cells
(NPCs) were propagated in Advanced DMEM/F12, 1% Glutamax,
1% N2 supplement 1% penicillin-streptomycin, 0.1% B27 supple-
ment, 10 ng/ml FGF and 10 ng/ml EGF. Coverslips were coated with
Matrigel (BD Biosciences) for 1hr, diluted 1:30 in DMEM.  NPCs were
plated in NPC propagation medium without mitogens for 24 h and
switched to Neurobasal-A, supplemented with 1% non-essential
amino acids, 1% N2 supplement, 1% penicillin-streptomycin, 0.5%
Glutamax, 10 ng/ml BDNF, 10 M forskolin, 0.1 M retinoic acid
for neuronal differentiation. 50 M DAPT [4] was included in the
ﬁrst medium change. These HESC-neuronal cultures are consistent
with those described in Gupta et al. [13] in cellular composi-
tion; 95% were neurons and the remainder astrocytes, conﬁrmed
by TuJ1 and GFAP immunostaining. Differentiation duration was
determined from the day of application of neuronal differentia-
tion medium to NPCs. The day before experiments, HESC-derived
neurons were removed from their trophic differentiation medium
into a trophically deprived, glutamate-free “minimal medium” [13],
which comprises 90% Salt-Glucose-Glycine (SGG) medium [2] and
10% MEM  (Minimal Essential Medium, Invitrogen).
Calcium-imaging: The day before imaging, HESC-derived neu-
rons were removed from their trophic differentiation medium
into a trophically deprived, glutamate-free minimum medium as
described above. HESC-neurons, identiﬁed by morphology and
conﬁrmed by TuJ1 immunostaining, were imaged at various time-
points in artiﬁcial cerebrospinal ﬂuid (aCSF) [39] on a 37 ◦C-heated
stage. Cells were loaded with 11 M Fluo-3 for 30 min  and washed
in aCSF. Coverslips were mounted in a perfusion chamber. Fluo-
3 ﬂuorescence images (excitation 488 nm/emission 520 nm)  were
taken at baseline and during saturating glutamate (200 M)  and
NMDA (150 M)  stimulation. Glycine (100 M)  was  applied as a
co-agonist. D-APV (50 M)  was used as an NMDAR antagonist.
For calibration, ionomycin was used to saturate the Fluo-3 sig-
nal (50 M),  followed by MnCl2 (10 mM)  to quench. The quenched
Fluo-3 signal corresponds to ∼100 nM Ca++. The Kd of Fluo-3 was
taken as 315 nM and free Ca++ concentration was calculated by
the formula Ca++ = Kd (F − Fmin)/(Fmax – F), where F is ﬂuorescence.
Images were taken every second for the duration of each experi-
ment (∼10 min) [17].
Gene expression analysis: Total RNA was isolated via the
Absolutely RNA miniprep kit, as described [13]. cDNA synthesis per-
formed via the AfﬁnityScript cDNA (Stratagene) synthesis kit using
oligo-dT and random hexamer primers, and qRT-PCR performed
using Brilliant SYBR Green master mix  (Stratagene), following
the manufacturer’s instructions. Forward and reverse primer
sequences: GRIN1 AGGAACCCCTCGGACAAGTT, CCGCACTCTCG-
TAGTTGTG; GRIN2A TGGACGTGAACGTGGTAGC, CCCCCATGAAT-
GCCCAAGAT; GRIN2B TTCCGTAATGCTCAACATCATGG, TGCTGCG-
GATCTTGTTTACAAA; GRIN2 C GAGTGGTCAAATTCTCCTACGAC,
TGTAGTACACCTCCCCAATCAT; GRIN2D CTGGCCTCACTGGATCTGG,
GGAAGGAAACCATAATCACGCA; GRIA1 GGTCTGCCCTGA-
GAAATCCAG, CTCGCCCTTGTCGTACCAC; GRIA2 AGTTTTC-
CACTTCGGAGTTCAG, CCAAATTGTCGATGTGGGGTG; GRIA3
TCCGGGCGGTCTTCTTTTTAG, TGGGGAATCCTCCGTGAGAAT; GRIA4
GCCATTGTCCCTGATGGAAAA, GAGGGGCAATAGCAATCTCTG;
GAPDH AGGCTGGGGCTCATTTG, CAGTTGGTGGTGCAGGAG.
Electrophysiology: Whole-cell NMDA-evoked currents were
recorded using an Axopatch 200B ampliﬁer (Molecular Devices)
using patch-pipettes made from thick-walled borosilicate glass
with a tip resistance of 4–8 M that were ﬁlled with an ‘inter-
nal’ solution that contained (in mM):  K-gluconate 141, NaCl 2.5,
HEPES 10, EGTA 11; pH 7.3 with KOH. Experiments were con-
ducted at room temperature (18–21 ◦C) in an ‘external’ solution
containing (in mM):  NaCl 150, KCl 2.8, HEPES 10, CaCl2 4, glucose
10, pH to 7.3 with NaOH. Picrotoxin (50 M),  strychnine (20 M)
and tetrodotoxin (300 nM)  were also included. NMDAR-mediated
currents were induced by the addition of saturating concentrations
of NMDA (100 M)  and the co-agonist glycine (100 M)  to the
external solution. Access resistances were monitored and recor-
dings where this changed by >20% were discarded. Currents were
ﬁltered at 2 kHz and digitised online at 5 kHz via a BNC-2090A/PCI-
6251 DAQ board interface (National Instruments, Austin, TX, USA).
Neuronal injury and Cell viability assays: The day before
application of the excitotoxic insult, HESC-derived neurons were
removed from their trophic differentiation medium into a troph-
ically deprived, glutamate-free minimal medium. Neurons were
treated with glutamate with and without MK801 (10 M)  [29].
24 h after excitotoxic challenge, cell viability was quantiﬁed using
CellTiter-Glo Luminescent Cell Viability Assay (Promega), following
manufacturer’s instructions. Neuronal injury experiments using
high-dose NMDA (150 M)  [29], were performed in magnesium-
free SGG medium [2]; cell viability was quantiﬁed after 24 h by the
same protocol.
Data analysis: All experiments were performed with at least 3
biological repeats; within each, 3 technical repeats were gener-
ated. qPCR data were normalised to GAPDH. Data are presented
as mean ± standard error of the mean; statistical analyses were
performed in Microsoft Excel and GraphPad Prism 5 (GraphPad
Software, Inc., San Diego) by univariate and two-way ANOVA with
Newman-Keuls post-test and two-tailed Students’ t-test. P < 0.05
was considered statistically signiﬁcant.
3. Results
3.1. Temporal proﬁle of in vitro acquisition of HESC-derived
neuronal glutamate responses
In order to study excitotoxic responses in a human platform,
enriched cultures of HESC-derived neurons were examined for
functional glutamate-mediated responses. Neurons were stimu-
lated with saturating glutamate (200 M)  and functional glutamate
receptor activity was  determined by calcium-imaging over increas-
ing duration in culture. While initially unresponsive to glutamate
(including doses of 1 mM glutamate: data not shown), HESC-
derived neurons developed calcium currents in response to
bath-extracellular glutamate application with increasing dura-
tion in culture. 2-week old HESC-derived neurons demonstrated
no signiﬁcant calcium inﬂux, while later time points demon-
strated signiﬁcant calcium inﬂux with glutamate treatment, with
peak calcium currents increasing over time to maximal at 6 and
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Fig. 1. HESC-derived neurons were differentiated from 2 to 8-weeks and stimulated with 200 M glutamate. (a) Development of glutamate-provoked calcium currents was
dependent on culture duration. (b) The proportion of glutamate-sensitive neurons in the cultures also increased over time. Peak calcium current and maximal proportion of
glutamate-responsive neurons were observed by 6-weeks in culture (*p < 0.001). HESC-derived neurons were investigated for NMDAR and AMPAR subunit expression at 2,
6  and 8-weeks in culture, by qRT-PCR. Signiﬁcant increases in (c) NMDA and (d) AMPA subunit expression were observed (*p < 0.01). Comparison with baseline ct values at
2-weeks suggested that GRIN1 and GRIN2B, and GRIA1 and GRIA2 were the most highly expressed receptor subunits at 6 and 8-weeks in culture.
8-weeks duration in culture (p < 0.001, Fig. 1a). The proportion
of HESC-derived neurons that exhibited glutamate-evoked cal-
cium currents similarly showed a time-dependent increase from
13 ± 3% at 2-weeks and 15 ± 1% at 3-weeks, 54.4 ± 5% at 4-weeks,
to 77.7 ± 4% and 73.0 ± 3% at 6 and 8-weeks respectively (p < 0.001,
Fig. 1b). Thus, HESC-derived neurons acquired functional glutamate
responsiveness over time in culture.
3.2. Development of functional glutamate responses coincides
with expression of NMDA and AMPA receptor subunits
In order to determine if the temporal emergence of glutamate-
responsiveness was due to increasing expression of glutamate
receptors, we quantiﬁed the expression of NMDAR and AMPAR
subunits in glutamate-unresponsive neurons at 2-weeks and in
glutamate-responsive neurons at 6 and 8-weeks by qRT-PCR.
The NMDAR is a heterotetramer of two  obligatory GluN1
subunits encoded by GRIN1,  and two variable GluN2 subunits
encoded by GRIN2 genes. Expression of NMDAR subunit GRIN1
increased from 2 to 6 and 8-weeks in culture by 1.9 ± 0.12-fold and
2.8 ± 0.25-fold respectively (p < 0.01). GRIN2A expression decreased
at 6 and 8-weeks, to 0.6 ± 0.04-fold and 0.6 ± 0.03-fold respec-
tively (p < 0.01). GRIN2B expression increased from 2-weeks to
1.4 ± 0.04-fold and 1.7 ± 0.01-fold and 6 and 8-weeks respectively
(p < 0.05). There was no signiﬁcant change in GRIN2C expression at
6 and 8-weeks (0.5 ± 0.13 and 1.5 ± 0.2-fold respectively). GRIN2D
expression increased to 1.3 ± 0.07 and 1.5 ± 0.1-fold at 6 and 8-
weeks respectively (p < 0.05, Fig. 1c). These data demonstrated
an increase in expression of NMDAR subunits GRIN1,  GRIN2B and
GRIN2D in HESC-derived neurons over 8-weeks in culture, but not
GRIN2A.  Analysis of ct values suggested that NMDAR subunits 1 and
2B were the most highly expressed.
AMPAR subunit quantiﬁcation showed that GRIA1 expression
increased signiﬁcantly from 2 to 6 and 8-weeks, by 2.0 ± 0.08
and 3.0 ± 0.3-fold respectively (p < 0.01). GRIA2 similarly increased
with duration in culture, to 1.8 ± 0.07-fold and 2.5 ± 0.04-fold after
6 and 8-weeks respectively (p < 0.01). GRIA3 and GRIA4 showed
no signiﬁcant change in expression at 6-weeks (1.0 ± 0.04-fold
and 1.0 ± 0.03-fold respectively) and a signiﬁcant, although mod-
est, increase in expression at 8-weeks (1.23 ± 0.027-fold and
1.22 ± 0.033-fold respectively, p < 0.05, Fig. 1d). These data demon-
strated an increase in AMPAR expression of HESC-derived neurons
over time in culture. Analysis of ct values suggested that AMPAR
subunits 1 and 2 were the most highly expressed.
The NMDAR and AMPAR proﬁles were dynamic over the course
of the period studied, with increasing expression of AMPAR and
NMDAR subunits GluN1 and GluN2B coinciding with the develop-
ment of functional glutamate responses in vitro. Given that during
development rodent neurons undergo a transition from GluN2B
subunit-containing NMDARs to GluN2A predominance [41], the
NMDAR subunit proﬁle in HESC-derived neurons may  change fur-
ther over time.
3.3. HESC-derived neurons express functional NMDA receptors
In order to determine whether the glutamate-induced cal-
cium inﬂux was  dependent on the expression of functional
NMDARs, receptor-mediated calcium currents were quantiﬁed
in 8-week HESC-derived neuronal cultures using NMDA-glycine
co-treatment. Data demonstrated that HESC-derived neurons
exhibited calcium currents upon NMDA application, which were
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Fig. 2. HESC-derived neurons were cultured for 6-weeks and stimulated with NMDA. (a) 100 M NMDA elicited intracellular calcium currents, which were blocked by
concurrent 50 M D-APV administration (NMDAR antagonist) (*p < 0.05). (b) Neuronal responses to NMDA were conﬁrmed by electrophysiology, demonstrating inward
currents with 50 M NMDA stimulation. (c) 7-week-old HESC-derived neurons were challenged with increasing glutamate concentrations in minimal medium, and cell
viability  assessed at 24 h after challenge. HESC-derived neurons were sensitive to glutamate-induced excitotoxic cell death, demonstrating 58 ± 6% cell death with 20 M
glutamate. (d) MK801, a non-speciﬁc NMDAR blocker, was  added to HESC-derived neurons simultaneously with 20 M glutamate challenge. Excitotoxic cell death was
quantiﬁed after 24 h. MK801 co-administration signiﬁcantly reduced glutamate-induced excitotoxic cell death (*p < 0.05). (e) HESC-derived neurons were challenged with
150  M NMDA and neuronal death quantiﬁed after 24 h. Both conditions described were performed in magnesium-free SGG medium, and compared to trophically-deprived
control medium (*p < 0.001).
blocked with application of D-APV, a selective NMDAR inhibitor
(p < 0.05, Fig. 2a). NMDAR currents were further conﬁrmed by
patch-clamp electrophysiology (Fig. 2b).
3.4. HESC-derived neurons demonstrate excitotoxic cell death at
pathophysiological glutamate concentrations, and are rescued by
MK801-mediated NMDA receptor blockade
The susceptibility of 7-week-old HESC-derived neurons to
glutamate-induced cell death was determined over a range of
concentrations. With increasing glutamate concentrations, increas-
ing cell death was observed: at 20 M,  58% ± 5.98%; at 40 M,
72 ± 6.45%; and at 80 M,  71 ± 6.64% cell death was noted (Fig. 2c).
100% cell death was induced with application of 50 M stau-
rosporine. As 20 M glutamate is in the pathophysiological range
for extracellular glutamate concentration in human traumatic brain
injury patients [5], MK801 was assayed against this concentration.
In vitro studies on rodent neurons demonstrated the efﬁcacy
of NMDAR antagonists in preventing excitotoxic neuronal death
[6]. To investigate the role of NMDARs in glutamate excitotoxic-
ity in our system, enriched HESC-derived neuronal cultures were
exposed to 20 M glutamate in the presence and absence of MK801
(10 M)  for 24 h. MK801 conferred a signiﬁcant neuroprotective
effect against glutamate-induced excitotoxic injury (33.2 ± 8.4%
cell death compared to control: 57.5 ± 3.4%; p < 0.05, Fig. 2d).
When challenged with 150 M NMDA, neuronal death was also
observed (27.7 ± 3.6%; p < 0.001, Fig. 2e), however at lower lev-
els than those induced by glutamate. Further work is required to
elucidate the downstream signalling pathways that mediate glu-
tamate and NMDA-induced excitotoxic neuronal dysfunction and
death. Establishment of a robust platform for functional glutamate
transmission and excitotoxicity in human neurons permits exam-
ination of these downstream pathways and could potentially aid
the discovery of novel therapeutic targets.
4. Discussion
Pathological stimulation of NMDAR by glutamate has been
implicated in excitotoxic injury and channel blockers have been
trialled in human conditions to poor effect [20], suggesting that
our understanding of human NMDAR-signalling is incomplete and
reliable human-based experimental models could be informative,
alongside animal studies. However, the development of glutamate-
dependent currents was  previously uncharacterised in enriched
HESC-derived neurons in vitro.
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In these studies, we demonstrate that HESC-derived neurons,
within the context of the current experimental platform, acquired
maturation-dependent glutamate-responsiveness over time in cul-
ture; knowledge of these characteristics is critical for the use
of HESC-neural derivatives in models of neurological injury. By
mRNA expression studies, there were large increases in transcrip-
tion of GRIN1 encoding the constitutive NMDAR1 subunit, GRIA1
encoding the AMPAR1 subunit, and modest increases in further
NMDAR and AMPAR subunit genes. These modest transcriptional
increases translated to the expression of functional and properly
assembled NMDARs as determined by functional studies herein,
utilising NMDA as a speciﬁc agonist and the selective inhibitor D-
APV. Furthermore, quantitative studies of current amplitude and
the proportion of glutamate-responsive cells demonstrated grad-
ual increase of receptor function over duration in culture, thus
suggesting neuronal-intrinsic modulation of glutamate-receptor
expression and functional downstream-signalling over time. Direct
conﬁrmation of NMDAR and AMPAR subunit proﬁles could be elu-
cidated further by electrophysiological studies with appropriate
subunit-speciﬁc inhibitors. The mRNA expression data also sug-
gested that NMDAR subunit expression was dynamic over the
in vitro time course, with GluN2B predominance. It remained to be
seen whether the subunit proﬁle would develop over time to reca-
pitulate the conversion from GluN2B to GluN2A predominance in
experimental mammalian systems [41].
In this study, glutamate was investigated as a physiologically
relevant stressor due to its direct pathophysiological role in dis-
ease states. Dose-survival curves demonstrated that HESC-derived
neurons underwent glutamate-induced cell death over the range
of concentrations seen in human brain injury patients in vivo [5],
and could be rescued with MK801 co-administration. Similar con-
centrations of glutamate and MK801 have also been demonstrated
to mediate excitotoxic cell death and protection in rodent in vitro
studies [7,37], and in human neurons derived from the human NT2
teratocarcinoma cell-line [14,32].
Interestingly, MK801 did not completely block glutamate-
mediated neuronal death and, furthermore, NMDA alone induced a
lower level of neuronal death than that mediated by glutamate.
These ﬁndings suggest other mechanisms of glutamate-induced
neuronal death in addition to NMDAR-mediated excitotoxic-
ity. Glutamate in high concentrations has been demonstrated
to cause oxidative-stress mediated neuronal death by compet-
itively inhibiting cystine uptake via the Xct cystine/glutamate
antiporter and impairing glutathione production [33,37]. While
the concentrations used to experimentally induce glutamate-
induced oxidative cell death are typically in the millimolar range
[36], excitotoxic neuronal death at lower glutamate concentra-
tions, mediated by NMDAR activation, has been shown to result
in further glutamate release and accumulation in medium to
higher concentrations capable of mediating oxidative neuronal
death [37]. Calcium-permeable AMPARs, lacking the GluR2 subunit
that prevents calcium permeability, have also been demonstrated
to mediate hippocampal neuronal death in rodent slice cul-
tures. Oxygen-glucose-deprivation increases synaptic-trafﬁcking
of GluR2-lacking AMPARs in CA1 hippocampal neurons, caus-
ing AMPAR mediated excitotoxic cell death [9]. The pre-exposure
of HESC-neurons to trophically-deprived medium in the current
experimental model may  have affected the trafﬁcking of AMPAR
and partially accounted for the MK801-insensitive excitotoxic neu-
ronal death observed.
5. Conclusions
Human pluripotent stem cell technology, including HESCs and
iPSCs, has tremendous potential for modelling neurological disease
processes. Technological advances have allowed the generation of
enriched human neurons and glia under deﬁned conditions, per-
mitting study of human neural cells in vitro [13,24,35]. Here, we
characterised a population of enriched HESC-derived neurons in
terms of development of glutamatergic responses and investigated
their utility in modelling glutamate-induced neuronal injury. We
established that after 2 months in culture, HESC-derived neurons
underwent excitotoxic cell death at concentrations of glutamate
found in the brains of human patients suffering acquired brain
injury, and thus have the potential to recapitulate aspects of human
pathophysiology. Furthermore, insights from the development and
reﬁnement of HESC-based platforms for in vitro modelling of neu-
ronal injury and rescue will be critical for the development of other
HPSC-based complementary systems, including iPSCs.
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